What is it about?
The guideline presented herein is the English translation of the revised third edition, issued in 2024. The aim is to enhance health outcomes for patients suffering from thyroid tumors by facilitating evidence-based shared decision-making between healthcare providers and patients, as well as standardizing the management of thyroid tumors.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The focus is on adult patients with thyroid tumors, addressing clinically significant issues categorized into areas such as an overview of the diagnosis and treatment of thyroid nodules, treatment strategies by histological type, radioactive iodine therapy, treatment of advanced differentiated carcinoma, pharmacotherapy, and complications and safety management associated with thyroid surgery. Thirty-two clinical questions were established in these areas.
Perspectives
Future challenges for the next revision are presented as "Future research questions".
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery, Endocrine Journal, January 2025, Japan Endocrine Society,
DOI: 10.1507/endocrj.ej24-0644.
You can read the full text:
Contributors
The following have contributed to this page
